A large percentage of human antibodies against S. aureus target wall teichoic acid (WTA), a ribitol-phosphate (RboP) surface polymer modified with N-acetylglucosamine (GlcNAc) 5, 6 . It is currently unknown whether the immune evasion capacities of MRSA are due to variation of dominant surface epitopes such as those associated with WTA. Here we show that a considerable proportion of the prominent healthcare-associated and livestock-associated MRSA clones CC5 and CC398, respectively, contain prophages that encode an alternative WTA glycosyltransferase. This enzyme, TarP, transfers GlcNAc to a different hydroxyl group of the WTA RboP than the standard enzyme TarS   7 , with important consequences for immune recognition. TarP-glycosylated WTA elicits 7.5-40-fold lower levels of immunoglobulin G in mice than TarS-modified WTA. Consistent with this, human sera contained only low levels of antibodies against TarP-modified WTA. Notably, mice immunized with TarS-modified WTA were not protected against infection with tarP-expressing MRSA, indicating that TarP is crucial for the capacity of S. aureus to evade host defences. High-resolution structural analyses of TarP bound to WTA components and uridine diphosphate GlcNAc (UDPGlcNAc) explain the mechanism of altered RboP glycosylation and form a template for targeted inhibition of TarP. Our study reveals an immune evasion strategy of S. aureus based on averting the immunogenicity of its dominant glycoantigen WTA. These results will help with the identification of invariant S. aureus vaccine antigens and may enable the development of TarP inhibitors as a new strategy for rendering MRSA susceptible to human host defences.
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Novel prevention and treatment strategies against major antibioticresistant pathogens such as MRSA are urgently needed but are not within reach because some of the most critical virulence strategies of these pathogens are not understood 8 . The pathogenic potential of prominent healthcare-associated (HA)-MRSA and recently emerged livestock-associated (LA)-MRSA strains is thought to rely on particularly effective immune evasion strategies, whereas communityassociated (CA)-MRSA strains often produce more aggressive toxins 1, 2 . Most humans have high overall levels of antibodies against S. aureus as a consequence of preceding infections, but antibody titres differ strongly for specific antigens and are often not protective in immunocompromised patients, for reasons that are not clear 3 . A large percentage of human antibodies against S. aureus is directed against WTA 5, 9, 10 , which is largely invariant. However, some S. aureus lineages produce altered WTA, which modulates, for instance, phage susceptibility 7, 11 . To investigate whether some prevalent S. aureus lineages use additional WTA-targeted strategies to increase their fitness and pathogenicity, we screened S. aureus genomes for potential additional paralogues of WTA biosynthesis genes. We found three S. aureus prophages that encoded a protein, TarP, that has 27% identity to the WTA-β-GlcNAc 
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transferase TarS 7 (Fig. 1a) . tarP was found exclusively in isolates of the prominent HA-MRSA CC5 12 , on a prophage that also encoded the scn, chp and sak immune evasion genes 13 , and on two other prophages in the emerging LA-MRSAs CC398 14 and CC5
15
. All tarP-harbouring genomes also contained tarS.
When tarP from CC5 HA-MRSA strain N315 was expressed in a WTA glycosylation-deficient mutant of laboratory strain RN4220 7 , it restored WTA glycosylation (Extended Data Fig. 1a ) and susceptibility to siphophages, which need RboP WTA GlcNAc as a binding motif 16 (Fig. 1b) . The presence of β-GlcNAc on WTA is essential for full β-lactam resistance in MRSA strains 7 . When tarP was expressed in a WTA glycosylation-deficient mutant of CA-MRSA strain MW2 (CC1), it restored full oxacillin resistance (Extended Data Fig. 1b) , confirming that tarP can replace tarS in several key interactions.
The expression of TarP led to susceptibility to siphophages, albeit to a lower extent than TarS (Extended Data Fig. 1c) , although TarP did not incorporate less GlcNAc into WTA than TarS (Extended Data Fig. 1d , Supplementary Table 3) . Similarly, the siphophage-mediated horizontal transfer of an S. aureus pathogenicity island was reduced about tenfold in S. aureus N315 expressing tarP, compared to the same strain expressing only tarS (Fig. 1c) , suggesting that TarP and TarS glycosylate WTA differently. Notably, N315 was resistant to podophages, but inactivation of tarP (but not of tarS) rendered it susceptible to podophages (Fig. 2a) . We analysed the overall effect of tarP on podophage susceptibility patterns in 90 clinical CC5 and CC398 isolates and found that none of the tarP-containing strains, but all of the tarP-lacking strains, were susceptible to podophages (Extended Data Table 1 ). Thus, TarP causes podophage resistance and TarP-mediated modification of WTA is distinct from that mediated by TarS. Nuclear magnetic resonance (NMR) analyses revealed that both TarP and TarS add GlcNAc to WTA in the β-configuration. However, the attachment site in RboP differs: TarS glycosylates the C4 position 17 whereas TarP attaches GlcNAc
N315
ΔtarP
Wild type
ΔtarPΔtarS ΔtarPΔtarS c-tarS
ΔtarPΔtarS c-tarP
ΔtarP c-tarP Table 2) . This difference may be crucial for impairing phage infection. Moreover, NMR analysis revealed that TarP is dominant over TarS because in N315, which bears both genes, GlcNAc was almost exclusively attached to RboP C3 (Fig. 2b) .
We solved the TarP structure at high resolution to elucidate how TarP generates a different glycosylation product from TarS. Like TarS   18 , TarP forms stable homotrimers, but it uses a different trimerization strategy because it lacks the C-terminal trimerization domain found in TarS (Fig. 2c, Extended Data Fig. 3 ). Instead, hydrophobic and polar interactions of a small helical C-terminal domain generate the TarP trimer (Fig. 2d, e) . WTA polymers comprising three or six RboP repeating units (3RboP or 6RboP-(CH 2 ) 6 NH 2 , respectively) were synthesized and used for soaking TarP crystals ( Supplementary Information Fig. 2, 3) , yielding the first protein structure visualizing the binding of a WTAbased polymer (Fig. 3, Extended Data Fig. 4 ). In the ternary complex TarP-UDP-GlcNAc-3RboP, the distance between the C3-hydroxyl of the third unit of 3RboP (RboP3) and the anomeric C1 of GlcNAc is 4.2 Å. Furthermore, at 3.1 Å, Asp181 is well within hydrogen bonding distance of the C3-hydroxyl of RboP3. The observed distances and geometry nicely explain the unusual glycosylation of WTA at the C3-hydroxyl. We propose that TarP uses a direct S N 2-like glycosyltransferase reaction, as discussed for other inverting GT-A fold enzymes 19, 20 . In this mechanism, Asp181 would act as the catalytic base, deprotonating the C3-hydroxyl on RboP3 and enabling a nucleophilic attack on the GlcNAc C1, thus yielding a β-O-GlcNAcylated polyRboP (Fig. 3c) . Mutagenesis of Asp181 to alanine rendered TarP inactive, supporting this putative mechanism (Extended Data Table 2 ).
The ternary structure of TarP-UDP-GlcNAc-3RboP allows us to predict how polyRboP binds to the homologous TarS enzyme. Three residues that are critical for binding and catalysis (including Asp181) are identical in TarP and TarS, while five other residues differ 18 ( Fig. 3d ). Lys255 and Arg262, for instance, which interact electrostatically with a WTA phosphate group in TarP, are replaced with Glu248 and Ser255, respectively, in TarS, which may lead to reduced affinity for WTA and might explain why TarP is dominant over TarS in vivo. On the basis of the location of UDP-GlcNAc, the identical Tyr149, Asp178 and Arg252 side chains, the conserved aromatic side chain of Phe256, and a site that contains a bound sulfate ion from the crystallization solution (S1) and probably binds phosphate in TarS (Fig. 3e) , the polyRboP chain would be shifted to the upper right, and the relative position of RboP units in the binding site would be altered in TarS. Such an altered binding mode would move the C4-hydroxyl of the target RboP towards C1 of GlcNAc, allowing TarS to glycosylate at the C4 position.
S. aureus WTA is a dominant antigen for adaptive immune responses 5, 9 . The observation that the position of GlcNAc on RboP had a profound impact on binding by podophage receptors raises the question of whether human antibodies also discriminate between the two isomeric polymers and whether MRSA clones use TarP to subvert immune recognition. We analysed several human antibody Letter reSeArCH preparations for their capacity to opsonize a panel of N315 strains with or without tarP and/or tarS. The mutant lacking any WTA glycosylation bound the lowest amount of IgG compared to WTA glycosylation-positive strains (Fig. 4a) , demonstrating that glycosylated WTA is a prominent S. aureus antigen in humans. Exclusive expression of tarS led to strongly increased IgG binding compared to the glycosylation-deficient mutant, indicating that β-GlcNAc on RboP C4 is an important epitope for human anti-S. aureus antibodies. By contrast, expression of tarP in the presence or absence of tarS led to only slightly increased IgG binding compared to the glycosylation-deficient mutant. The capacity of TarP to impair the deposition of IgG on S. aureus differed with individual serum donors and reached average levels in pooled serum preparations (Fig. 4a) . When tarP was deleted in three further CC5 isolates, they showed similarly increased capacities to bind human serum antibodies compared to the wild-type strains (Extended Data Fig. 1e ). Additionally, tarP deletion led to a substantially increased capacity of human neutrophils to phagocytose opsonized S. aureus (Fig. 4b , Extended Data Fig. 1g) . Thus, only a small percentage of S. aureus-specific antibodies can bind WTA with β-GlcNAc on RboP C3, and tarPexpressing S. aureus are less likely to be detected and eliminated by human phagocytes.
We purified N315 WTA that had been glycosylated by TarS or TarP and used it to immunize mice. Antibodies binding to regular (TarS-modified) WTA increased continuously over three weeks after vaccination (Fig. 4c) . By contrast, no or only very low amounts of IgG directed against TarP-glycosylated WTA emerged, indicating that WTA modified at RboP C3 is much less immunogenic than WTA modified at RboP C4. This experiment was repeated three times with three different WTA preparations and yielded broadly similar data.
Vaccination with S. aureus WTA bearing GlcNAc at RboP C4 protects mice against infection by CA-MRSA strains USA300 (CC8) or USA400 (CC1), which both lack tarP 5, 21 . Remarkably, vaccination with regular (TarS-modified) or TarP-modified WTA did not lead to any notable protection against subsequent infection with tarP-expressing N315 compared to mock vaccination, despite the robust antibody response against regular WTA (Fig. 4d) . Together, our results demonstrate that tarP protects S. aureus against adaptive host defences by allowing bacteria to evade recognition by preexisting anti-S. aureus antibodies and by exploiting the poor immunogenicity of TarP-modified WTA.
It is possible that TarP-modified WTA mimics a currently unknown autoantigen and is therefore hardly immunogenic. On the other hand, regular S. aureus WTA can be ingested by antigen-presenting cells Letter reSeArCH and presented to T cells, in a largely unexplored way, thereby evoking specific immunoglobulins and immunological memory 22, 23 . It is possible that TarP-modified WTA is refractory to this process. Thus, TarSand TarP-modified WTA could be helpful for decoding glycopolymer presentation pathways and for defining the most promising WTA epitopes for the development of protective vaccines against S. aureus.
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Protection against S. aureus infections is urgently needed, in particular for hospitalized and immunocompromised patients 2, 4 . Antibodies can in principle protect against S. aureus, but their titres and specificities vary largely among humans and they are often not protective in immunocompromised patients 3 , probably in particular against S. aureus clones that mask dominant epitopes, for instance using TarP. Unfortunately, all previous human vaccination attempts with protein or glycopolymer antigens have failed, for reasons that are unclear 24 .
Our study identifies a new strategy used by pandemic MRSA clones to subvert antibody-mediated immunity, which should be considered in future vaccination approaches. S. aureus WTA with GlcNAc at RboP C3 has been reported as a type-336 antigen, but was not further explored 25 . We found that tarP is present in type-336 S. aureus (Extended Data  Fig. 1f) . However, TarP-modified WTA is a very poor antigen and vaccines directed against GlcNAc at WTA RboP C3 or C4 may fail against many of the pandemic MRSA clones. The structural characterization of TarP will instruct the development of specific TarP inhibitors that could become important in combination with anti-WTA vaccines or antibiotic therapies. We found tarP-encoding prophages in 70-80% of south-west German HA-MRSA CC5 and 40% of Danish LA-MRSA CC398 isolates (Extended Data Table 1 ), pointing to a crucial role of tarP in the fitness of these lineages and raising concerns of further dissemination by horizontal gene transfer. TarP is a new and probably crucial component of the S. aureus virulence factor arsenal 26, 27 , highlighting the important roles of adaptive immunity and its evasion in S. aureus infections.
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No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Bacterial strains and growth conditions. S. aureus strains N315, RN4220, and MW2 (wild type and mutants) were used for this study. Collections of CC5 isolates of the Rhine-Hesse pulsed-field gel electrophoresis type 28 and of the LA-MRSA lineage CC398 from the Danish Statens Serum Institut 29, 30 were analysed for the presence of tarP and for podophage susceptibility. Additionally, 48 spa-type t002 (ST5) and 16 spa-type t003 (ST225) isolates were obtained from the MRSA collection of the University Hospital Tübingen and analysed for tarP presence by PCR. S. aureus strains were cultivated in tryptic soy broth (TSB) or basic medium (BM; 1% tryptone, 0.5% yeast extract, 0.5% NaCl, 0.1% glucose, 0.1% K 2 HPO 4, w/v). MICs of oxacillin were determined by microbroth dilution according to established guidelines 31 . Experiments with phages. tarP-encoding phages were identified in genome sequences using the webtool Phaster 32 in representative strains listed with GenBank accession: ΦtarP-Sa3int with immune evasion cluster (IEC) in CC5 (strain N315, BA000018.3), ΦtarP-Sa1int, found in LA-MRSA of CC5 (strain ISU935, CP017090), and ΦtarP-Sa9int found in CC398 (strain E154, CP013218).
Phage susceptibility was determined using a soft-agar overlay method 16 . In brief, 10 µl phage lysate of 10 4 -10 6 PFU was dropped onto soft agar containing 100 µl bacterial suspension (OD 600 of 0.1). Plates were incubated at 37 °C overnight. The efficiency of plating was determined as described 33 . Transfer of SaPIs was determined according to previously described methods 11 . In brief, SaPI particle lysates were generated from S. aureus strain JP1794, which encodes a SaPI with a resistance marker for tetracycline 34 . PFU of SaPI lysate was determined on RN4220. 200 µl bacterial culture (OD 600 of 0.5) was mixed with 100 µl of SaPI particle lysate (SaPIbov1 (Φ11), 10 6 PFU/ml), incubated at 37 °C for 15 min. Appropriate dilutions were plated on TSB plates containing 3 µg/ml of tetracycline, and CFU were checked after overnight incubation. WTA isolation and structure analysis. WTA from S. aureus was isolated and purified according to previously described methods 11 . In brief, WTA was released from purified peptidoglycan by treatment with 5% trichloroacetic acid and dialysed extensively against water using a Spectra/Por3 dialysis membrane (MWCO of 3.5 kDa; VWR International GmbH). Obtained soluble WTA was quantified by determining the content of phosphate 35 and GlcNAc
36
. For PAGE analysis of WTA, samples (400 nmol of phosphate per lane) were applied to a 26% polyacrylamide (Rotiphorese Gel 40 (19:1)) resolving gel and separated at 25 mA for 16 h 37 . The gel was equilibrated in a solution of 40% ethanol and 5% acidic acid at room temperature for 1 h and the WTA ladders were visualized by incubation with alcian blue (0.005%) for several hours.
NMR spectroscopy experiments were carried out on a Bruker DRX-600 spectrometer equipped with a cryo-probe, at 288 K (WT-WTA, TarS-WTA, and TarP-WTA) or 298 K (double-mutant WTA lacking any glycosylation). Chemical shifts of spectra recorded in D 2 O were calculated in p.p.m. relative to internal acetone (2.225 and 31.45 p.p.m.). The spectral width was set to 10 p.p.m. and the frequency carrier placed at the residual HOD peak, suppressed by pre-saturation. Two-dimensional spectra (TOCSY, gHSQC, gHMBC, and HSQC-TOCSY) were measured using standard Bruker software. For all experiments, 512 FIDs of 2,048 complex data points were collected, 32 scans per FID were acquired for homonuclear spectra, and 20 or 100 ms of mixing time was used for TOCSY spectra. Heteronuclear 1 H- 13 C spectra were measured in the 1 H-detected mode, gHSQC spectrum was acquired with 40 scans per FID, the GARP sequence was used for 13 C decoupling during acquisition; gHMBC scans doubled those of gHSQC spectrum. As for HSQC-TOCSY, the multiplicity editing during selection step version was used, scans tripled those of the HSQC spectrum and two experiments were acquired by setting the mixing time to 20 or 80 ms. During processing, each data matrix was zero-filled in both dimensions to give a matrix of 4K × 2K points and was resolution-enhanced in both dimensions by a cosine-bell function before Fourier transformation; data processing and analysis were performed with the Bruker Topspin 3 program. Molecular biology. All primers used for PCR, cloning, and mutagenesis are listed in Supplementary Table 1 . tarP (UniProt A0A0H3JNB0, NCBI Gene ID 1260584) was amplified using genomic DNA of S. aureus N315 and inserted in Eschericha coli/S. aureus shuttle vector pRB474 38 at the BamHI and SacI sites, to transform S. aureus, or into pQE80L at BamH1 and HindIII sites, to transform E. coli BL21(DE3). A thrombin cleavage site was inserted between the His-tag and mature protein in pQE80L. Single mutations of TarP were introduced by PCRbased site-directed mutagenesis 39 . The obtained amplicons were confirmed by sequencing. For the construction of marker-less S. aureus deletion mutants of tarS or tarP, the pIMAY shuttle vector was used 40 . The IgG-binding surface protein A gene (spa) was deleted using the pKORI shuttle vector 41 . Protein A deletion had no impact on phage siphophage or podophage susceptibility, indicating that it did not alter WTA amount or structure. Protein expression, purification, and activity assay. E. coli BL21(DE3) were grown in LB medium at 30 °C. Expression of tarP was induced with 1 mM IPTG at 22 °C at an OD 600 of 0.6. After 15 h, cells were harvested, washed with wash buffer (50 mM Tris-HCl, pH 8.0, 1 mM EDTA), and lysed by sonication with lysis buffer (70 mM NaH 2 PO 4 , pH 8.0, 1 M NaCl, 20% glycerol, 10 U/ml of benzonase nuclease). After centrifugation (15,000g), the supernatant was filtered with a 0.45 µm filter, loaded onto a His Trap FF column (GE Healthcare, 5 ml), and washed with buffer A (50 mM NaH 2 PO 4 , pH 8.0, 1 M NaCl, 20% glycerol) supplemented with 45 mM imidazole and buffer B (buffer A with 90 mM imidazole). Finally, the protein was eluted with buffer C (buffer A with 500 mM imidazole), and the fractions were pooled, and further purified by size-exclusion chromatography on a Superdex 200 10/30 column equilibrated with buffer D (20 mM MOPS, pH 7.6, 400 mM LiCl, 10 mM MgCl 2 , 5 mM β-mercaptoethanol, 5% glycerol). The peak fractions were pooled and concentrated to 1.4 mg/ml for crystallization. For selenomethionyl-form TarP production, bacteria were grown in a selenomethionine-containing medium (Molecular Dimension) and auto-induction was carried out. The protein was purified as described above. The activity of wild-type and mutated TarP, as well as donor substrate specificity of TarP were determined with the ADP Quest Assay kit (DiscoverRx, Extended Data Tables 2, 3 ). The reaction volume was 20 µl with 1 mM UDP-GlcNAc, 1.5 mM purified WTA from RN4220 ΔtarM/S. The reaction was started with protein and incubated at room temperature for 1 h. Released UDP, coupled into a fluorescence signal, was detected in a 384-well black assay plate with 530 nm excitation and 590 nm emission wavelengths using TECAN Infinite M200. were used for soaking of synthetic 3RboP (60 mM), 6RboP-(CH 2 ) 6 NH 2 (41 mM), or UDP-GlcNAc (20 mM) combined with 3RboP (52 mM) for 5 min. For data collection the crystals were cryo-protected with 20% glycerol in reservoir solution and flash-frozen in liquid nitrogen. Diffraction data were collected at beamline X06DA of Swiss Light Source in Villigen, Switzerland, or at beamline BL14.1 at BESSY-II, Helmholtz Zentrum Berlin. Phasing, model building, and refinement. For phase determination, two data sets from a selenomethionine-containing TarP crystal were collected at wavelengths of 0.97941 Å (peak) and 0.97952 Å (inflection). The structure was solved by multiwavelength anomalous dispersion (MAD) at 2.60 Å resolution. All data were reduced using XDS/XSCALE software packages 42 . Initial phases were derived from the substructure of 26 selenium atom sites per asymmetric unit with the program suite SHELX C/D/E 43 . The heavy atom parameters were further refined and the initial phases were improved by SHARP/autoSHARP 44 . The initial model was generated with PHENIX 45 and the final model was achieved by cycles of iterative model modification using COOT 46 , and restrained refinement with REFMAC. TLS was used in the later stages 47, 48 . The four binary and one ternary complex structures were solved by molecular replacement using PHASER 49 and the unliganded TarP structure was used as a search model. UDP-GlcNAc, 3RboP, Mg 2+ , or Mn 2+ were removed from the models to calculate the simulated annealing (mF o − DF c ) omit maps using PHENIX. The anomalous difference map of Mn 2+ at 1.89259 Ǻ was generated by FFT within CCP4, from which two Mn 2+ in the active site and one Mn 2+ at the trimer interface were identified. The coordinate and parameter files for 3RboP and 6RboP-(CH 2 ) 6 NH 2 were calculated using the PRODRG server 50 . The structure figures were generated by PyMOL 51 and the models were evaluated using MolProbity 52 . Statistics for the data collection, phasing, and refinement are reported in Extended Data Tables 4 and 5 . Synthesis of ribitol phosphate oligomers. Synthesis of 3RboP. Target compound 1, d-ribitol-5-phosphate trimer (3RboP), was prepared by the phosphoramidite method 53, 54 ( Supplementary Fig. 2 ). In brief, the primary alcohol of commercially available compound 2 was converted into levulinoyl ester by using levulinic acid and N,N'-dicyclohexylcarbodiimide (DCC), and the allyl group of 3 was removed with tetrakis(triphenylphosphine)palladium to produce compound 4. The primary alcohol of 4 reacted with phosphine derivative 5 in the presence of diisopropylammonium tetrazolide 55 to generate phosphoramidite 6. At the same time, compound 4 was coupled with dibenzyl N,N-diisopropylphosphoramidite 7, which was catalysed by 1H-tetrazole, and the product was further oxidized by tert-butyl hydroperoxide, yielding protected d-ribitol-5-phosphate 8. Cleavage of the levulinoyl ester of 8 with hydrazine hydrate resulted in benzyl protected d-ribitol-5-phosphate 9, which was further coupled with phosphoramidite 6 and oxidized with tert-butyl hydroperoxide to yield protected dimers of d-ribitol-5-phosphate 10. After removal of the levulinoyl group, the dimer 11 was coupled with phosphoramidite 6 using the same conditions as above to obtain a protected trimer of d-ribitol-5-phosphate 12. Subsequent removal of the levulinoyl group and hydrogenolysis of 13 to remove all benzyl groups yielded 3RboP 1. All chemicals and experimental procedures as well as characterization of products can be found in the Supplementary Methods. Synthesis of 6RboP-(CH 2 ) 6 NH 2 . Aminohexyl d-ribitol-5-phosphate hexamer (6RboP-(CH 2 ) 6 NH 2 ) was synthesized using a new method (Supplementary Fig. 3 ). All chemicals (Acros, Biosolve, Sigma-Aldrich and TCI) for the synthesis were used as received and all reactions were performed under a protective argon atmosphere at room temperature, unless otherwise stated. Procedures for phosphoramidite coupling, oxidation, detritylation, global deprotection, TLC analysis and characterization of these compounds can be found in Supplementary Methods. Human samples. Venous blood samples were obtained from male and female healthy volunteers (20-50 years) with protocols approved by the Institutional Review Board for Human Subjects at the University of Tübingen (014/2014BO2 und 549/2018BO2). Informed written consent was obtained from all volunteers. Blood samples were used for purification of either serum IgGs or neutrophils as described below. IgG from human plasma. IgG was purified from plasma of human donors using the NAb Protein G Spin Kit (ThermoFisher), purity was checked by SDS PAGE, and protein concentration was determined using Bradford assay. Anti-WTA-IgG was prepared as described 9 . To analyse the IgG-binding capacity of S. aureus cells, exponentially growing bacterial cultures were adjusted to an OD 600 of 0.5, diluted 1:10 in PBS, and 100 µl of diluted bacteria was mixed with 100 µl of IgG diluted in PBS with 1% BSA. The concentration of IgG was 250 ng/ml for IgG enriched for WTA binding, 10 µg/ml for IgG from pooled human serum (Athens R&T 16-16-090707, Abcam ab98981), or 5 µg/ml for single-donor IgG preparations. A control without IgG was included in all experiments for all mutants. Samples were incubated at 4 °C for 1 h, centrifuged, washed 2-3 times with PBS, and further incubated with 100 µl FITC-labelled anti-human IgG (Thermo Scientific, 62-8411, 1:100 in PBS with 1% BSA, 62-8411) at 4 °C for 1 h. Bacteria were centrifuged, washed 2-3 times with PBS, and fixed with 2% paraformaldehyde (PFA). Surface-bound IgG was quantified by flow cytometry using a BD FACSCalibur. For all flow cytometry experiments a mutant panel lacking spa, the gene for the IgG-binding protein A, was used. The subsequent gating strategy is exemplified in Extended Data Fig. 5a . IgG-mediated phagocytosis. Stationary-phase S. aureus cells were washed once with PBS and labelled by incubation in PBS containing 10 µM carboxyfluorescein succinimidyl ester (CFSE; OD 600 of 1.7) at 37 °C for 1 h. The bacteria were washed three times and resuspended in PBS. CFU were determined by plating on TSB plates and bacteria were heat-inactivated at 70 °C for 20 min. CFSE-labelled S. aureus (1 × 10 7 cells/ml) in PBS with 0.5% BSA were opsonized with anti-WTAIgG (0.15 or 0.3 ng/µl) at 4 °C for 40 min. Neutrophils from human donors, isolated via Ficoll-Histopaque density gradient centrifugation 56 , were diluted to a concentration of 2.5 × 10 6 /ml in neutrophil medium (10% HSA, 2 mM l-glutamine, 2 mM sodium pyruvate, 10 mM HEPES). 200 µl neutrophil suspension was incubated with 25 µl opsonized bacteria (final MOI 0.5) in a 96-well plate at 37 °C for 30 min, centrifuged (350g, 10 min), washed once with 200 µl PBS, and fixed with 2% PFA at room temperature for 15 min. Cells were washed twice with PBS and analysed by flow cytometry, whereby surface-bound and ingested bacteria were measured without discrimination. An example of the neutrophil gating strategy can be found in Extended Data Fig. 5b . Mice. Six-week-old sex-matched wild-type C57BL/6J mice, purchased from ORIENT BIO (Charles River Breeding Laboratories in Korea), were kept in micro-isolator cages in a pathogen-free animal facility. The conducted experiments were performed according to guidelines and approval (PNU-2017 (PNU- -1503 by the Pusan National University-Institutional Animal Care and Use Committee (PNU-IACUC). Sample size was chosen to obtain significant outcomes (alpha error ≤ 5%), based on results from previous experiments 21 . Experiments were performed in a non-blinded, non-randomized fashion. Mouse vaccination and infection. 30 µg of purified WTA from S. aureus N315 wild-type or isogenic ΔtarP, or ΔtarS mutants was dissolved in 15 µl PBS and mixed with the same volume of aluminium hydroxide gel adjuvant (Alhydrogelr 1.3%, 6.5 mg/ml, Brennatag). The mixtures were incubated at 37 °C with agitation for 1 h and injected three times at one-week intervals via mouse footpads. Seven days after the third injection, blood was obtained from the retro-orbital sinus and centrifuged (9,000g) at 4 °C for 10 min. The supernatants were aliquoted (50 µl) and stored at -80 °C for ELISA quantification of WTA-binding IgG as described 57 . Sera were diluted 1:100 and tested by ELISA on 96-well plates coated with 2.5 µg/ml sonicated WTA preparations (WTA from N315, ΔtarS or ΔtarP, respectively).
To prepare an inoculum for infection, N315 wild-type bacteria were grown in TBS at 37 °C with agitation (180 r.p.m.) until they reached an OD 600 of 1.0. After centrifugation (3,500g) at 4 °C for 10 min, bacteria adjusted to 5 × 10 7 CFU in 50 µl PBS containing 0.01% BSA were intravenously injected (n = 5 per group). Injected bacterial numbers were verified by plating serial dilutions of the inoculum onto TSA plates. To determine residual bacterial dissemination to kidneys, challenged mice were euthanized, and organs were extracted aseptically and homogenized in 1 ml of saline using a Polytron homogenizer (PT3100). The homogenates were serially diluted and plated on TSA to determine CFU counts. CFU were calculated per 1 ml of kidney. Statistical analyses. Statistical analysis was performed by using GraphPad Prism (GraphPad Software, Inc.). Statistically significant differences were calculated by appropriate statistical methods as indicated. P values of ≤ 0.05 were considered significant. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
All major data generated or analysed in this study are included in the article or its supplementary information files. The coordinates and structure factors were deposited in the Protein Data Bank under accession numbers 6H1J, 6H21, 6H2N, 6H4F, 6H4M and 6HNQ. Source data for experiments with animals ( Fig. 4c, d ) are provided. Additionally, a gel image of Extended Data Fig. 1f is supplied as Supplementary Fig. 1 . All other data relating to this study are available from the corresponding authors on reasonable request. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code Data collection -Genomes containing tarP were identified by the BLAST algorithm (URL: https://blast.ncbi.nlm.nih.gov/Blast.cgi), by using the amino acid sequence of TarP of S. aureus N315 (gene SA1808) as query. DA+ GUI, DA+ Server, Diffraction Viewer -Albula (version 3.2.0), and Data Processing Tracker were used for data collection of TarP structures at the beamline X06DA of Swiss Light Source in Villigen, Switzerland and Beamline-Control GUI (MXCuBE version 1) was used at the beamline BL14.1 in BESSY-II, Helmholtz Zentrum Berlin. For data reducing, phasing, model building, and refinement XDS package (BUTLT=20160617), XSCALE (BUTLT=20131111), SHELX C/D/E (2013/2), SHARP (2.8.6)/autoSHARP (3.10.6), PHENIX (1.13-2998), COOT (0.8.9.1 EL (CCP4)), REFMAC (CCPInterface 7.0.045), PHASER (CCP4Inetrface 7.0.044), FFT (CCP4Interface 7.0.052), CCP4 (7.0.062), PRODRG (CCP4Interface 7.0.062) were used. The structural figures were generated using PyMOL (1.8.4.1) and the models were valuated using MolProbity (4.02b-467).
-NMR spectra were acquired, processed and analyzed by using Bruker TopSpin 3.1 software for WTA elucidation. For synthesis of chemical compounds Bruker TopSpin 2.1 was used.
Data analysis -tarP-containing genomes were analyzed by the web-tool PHASTER (URL: http://phaster.ca/). -Statistical analysis was performed by using GraphPad Prism (GraphPad 419 Software, Inc.) Version 6.
-NMR spectra of WTA were analyzed by using Bruker TopSpin 3.1 software -Data analysis of NMR of chemical compounds MestReNova; Mnova 12.0.3 was used For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Data Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability All major data generated or analyzed in this study are included in the article or its supplementary information files. The coordinates and structure factors were deposited in the Protein Data Bank under accession numbers 6H1J, 6H21, 6H2N, 6H4F. and 6H4M and 6HNQ. Source data of experiments with animals (Fig 4c, d) , and Gel electrophoresis (Extended data Fig. 1f ) are provided as source data. All other data relating to this study are available from the corresponding authors on reasonable request.
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Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
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For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Sample sizes of in vitro and in vivo experiments were chosen to obtain significant results. The prospective power analysis was performed with appropriate statistical methods.
Data exclusions One data point ( = one mouse) was not included in the alum control of experiment 
Replication
Each major experiement was repeated at least three times as stated in the manuscript. In case of neutrophil phagocytosis assays results exhibited the typical strong donor-specific differences but similar trends between bacterial test strains. Therefore, a typical experiment, representative of 3 independet experiments is shown as stated in the figure legend. The other 2 replicates can be found in the Supplementary Information.
Randomization Neutrophils and plasma IgGs were obtained from three independent randomly selected donors to control for donor-specific differences in the prior exposure to S. aureus antigens.
Blinding
Blinding was not necessary in our study.
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